Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Caribou Biosciences Inc CRBU

Healthcare Biotechnology
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to... see more

Current News (NDAQ:CRBU)

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire 4 days ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire 13 days ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

GlobeNewswire 13 days ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

GlobeNewswire 13 days ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

GlobeNewswire November 2, 2025

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

GlobeNewswire August 25, 2025

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 12, 2025

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire July 25, 2025

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire May 28, 2025
View More News ››

Opinion & Analysis (NDAQ:CRBU)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CRBU)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway
coolfooldumbguy - 13 days ago

Phase 3 trial explained

https://www.oncologypipeline.com/apexonco/asco-2024-new-matching-strategy-delays-caribou https://www.oncologypipeline.com/apexonco...
Napcoo - June 28, 2024

$5.14, 29 March 2024 enter now or wait?

Seem like a good stock, but definitely not popular
Napcoo - March 29, 2024
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »